Riding the Trend or Protecting Profits | Protalix BioTherapeutics Inc. (PLX) – News Heater
Home  »  Companies   »  Riding the Trend or Protecting Profits | Protalix ...

Riding the Trend or Protecting Profits | Protalix BioTherapeutics Inc. (PLX)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Protalix BioTherapeutics Inc. (AMEX:PLX) went up by 0.95% from its latest closing price compared to the recent 1-year high of $7.02. The company’s stock price has collected -14.52% of loss in the last five trading sessions. Press Release reported on 06/05/21 that SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. – PLX

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Protalix BioTherapeutics Inc. (AMEX :PLX) Right Now?

Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Protalix BioTherapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



The average price from analysts is $9.75. PLX currently public float of 29.81M and currently shorts hold a 8.76% ratio of that float. Today, the average trading volume of PLX was 1.60M shares.

PLX’s Market Performance

PLX stocks went down by -14.52% for the week, with a monthly drop of -30.03% and a quarterly performance of -54.41%, while its annual performance rate touched -44.94%. The volatility ratio for the week stands at 6.75% while the volatility levels for the past 30 days are set at 6.36% for Protalix BioTherapeutics Inc.. The simple moving average for the period of the last 20 days is -22.09% for PLX stocks with a simple moving average of -46.89% for the last 200 days.

Analysts’ Opinion of PLX

Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08th of the previous year 2020.

Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.

Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.

PLX Trading at -46.54% from the 50-Day Moving Average

After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.80% of loss for the given period.

Volatility was left at 6.36%, however, over the last 30 days, the volatility rate increased by 6.75%, as shares sank -27.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.89% lower at present.

During the last 5 trading sessions, PLX fell by -14.52%, which changed the moving average for the period of 200-days by -44.21% in comparison to the 20-day moving average, which settled at $2.68. In addition, Protalix BioTherapeutics Inc. saw -41.60% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PLX starting from Dexcel Pharma Technologies Ltd, who sale 857,506 shares at the price of $2.25 back on Jun 03. After this action, Dexcel Pharma Technologies Ltd now owns 3,637,314 shares of Protalix BioTherapeutics Inc., valued at $1,932,304 using the latest closing price.

Dexcel Pharma Technologies Ltd, the 10% Owner of Protalix BioTherapeutics Inc., sale 61,211 shares at $2.56 during a trade that took place back on Jun 02, which means that Dexcel Pharma Technologies Ltd is holding 4,494,820 shares at $156,553 based on the most recent closing price.

Stock Fundamentals for PLX

Current profitability levels for the company are sitting at:

  • +4.31 for the present operating margin
  • +82.71 for the gross margin

The net margin for Protalix BioTherapeutics Inc. stands at -10.37.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of 2.09, with the company’s debt to enterprise value settled at 0.49. The receivables turnover for the company is 18.78 and the total asset turnover is 1.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Arrival (ARVL) Just Got Our Attention

Arrival (NASDAQ:ARVL) went down by -1.79% from its latest closing price compared to the recent 1-year high of $37.18. The company’s stock price has collected

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.